{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-051393","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.202114+00:00","generated_at":"2026-06-16T08:21:44.322723+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CVRx Q1 revenue $8.0M (+96% YoY); US HF sales surge 132%; raises full-year guidance","bullets":["Net loss of $11.4M ($0.55 per share) vs $10.0M ($0.49) in prior year quarter.","U.S. heart failure revenue $6.8M (+132% YoY); active implanting centers grew to 122 (118% YoY).","FY 2023 revenue guidance raised to $35.5M-$38.0M (prior $35M-$38M); gross margin guidance improved to 80%-83%.","Q2 2023 revenue expected between $8.2M and $8.8M; operating expenses $76M-$80M for full year.","Cash and equivalents $103.3M at quarter end; net cash used in ops and investing $10.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-051393","json":"https://secwatch.observer/filing/0001104659-23-051393.json","markdown":"https://secwatch.observer/filing/0001104659-23-051393.md","text":"https://secwatch.observer/filing/0001104659-23-051393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465923051393/0001104659-23-051393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465923051393/tm2313916d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T08:21:44.322723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"57a1b219e902ef26895a837c700319968076f2aa","claim":"CVRx, Inc. reported the first quarter of 2023 results: revenue $8.0 million, net income Net loss was $11.4 million, or $0.55 per share, EPS $0.55 per share. Guidance reaffirmed.","evidence_excerpt":"year quarter ● Active implanting centers in the U.S. grew to 122, an increase of 118% over the first quarter of 2022 ● Worldwide revenue for the first quarter of 2023 was $8.0 million, an increase of 96% over prior year quarter “I am thrilled with our first quarter performance, which demonstrated solid execution on multiple fronts. We were able to share the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1235912/000110465923051393/0001104659-23-051393-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Revenue","value":"$8.0 million"},{"label":"Net income","value":"Net loss was $11.4 million, or $0.55 per share"},{"label":"EPS","value":"$0.55 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}